DOI: 10.1055/s-00000116

Seminars in Vascular Medicine

Issue 03 · Volume 5 · August 2005 DOI: 10.1055/s-002-4308 Ximelagatran as a New Oral Anticoagulant for Thrombosis Editor in Chief Jan Jacques Michiels M.D. Ph.D., Guest Editors Ola E Dahl M.D. Ph.D.

  • C1

    Review Questions

  • 227
    Gustafsson, David:

    Discovery of Ximelagatran in an Historical Perspective

  • 235
    Mattsson, Christer; Sarich, Troy C.; Carlsson, Stefan C.:

    Mechanism of Action of the Oral Direct Thrombin Inhibitor Ximelagatran

  • 245
    Wolzt, Michael; Sarich, Troy S.; Eriksson, Ulf G.:

    Pharmacokinetics and Pharmacodynamics of Ximelagatran

  • 254
    Wolzt, Michael; Sarich, Troy S.; Eriksson, Ulf G.:

    Low Potential for Interactions Between Melagatran/Ximelagatran and Other Drugs, Food, or Alcohol

  • 259
    Carlsson, Stefan C.; Schulman, Sam:

    A Step Change in Oral Anticoagulation: Lack of Coagulation Monitoring with Ximelagatran

  • 266
    Colwell, Clifford; Mouret, Patrick:

    Ximelagatran for the Prevention of Venous Thromboembolism Following Elective Hip or Knee Replacement Surgery

  • 276
    Huisman, Menno V.; Bounameaux, Henri:

    Treating Patients with Venous Thromboembolism: Initial Strategies and Long-Term Secondary Prevention

  • 285
    Olsson, S. Bertil; Halperin, Jonathan L.:

    Prevention of Stroke in Patients with Atrial Fibrillation

  • 293
    Wallentin, Lars:

    Prevention of Cardiovascular Events after Acute Coronary Syndrome

  • 301
    Schulman, Sam; Lip, Gregory Y. H.:

    Ximelagatran in the Clinic: Practical Management of Patients

    • PREFACE

  • 223
    Dahl, Ola E.; Michiels, Jan Jacques:

    Ximelagatran as a New Oral Anticoagulant for Thrombosis